PASS · OBS13434 - SAN-ALE-2015-01
This prospective, multicenter, post-authorization observational study (PASS) evaluates the long-term safety profile of LEMTRADA® (alemtuzumab) treatment in patients diagnosed with relapsing forms of multiple sclerosis.
A Prospective, Multicenter, Observational Post-authorization Safety Study to Evaluate the Long Term Safety Profile of LEMTRADA® (Alemtuzumab) Treatment in Patients with Relapsing Forms of Multiple Sclerosis. Estudio PASS
Sponsor: SANOFI GENZYME
Phase: IV
Status: Follow-up